Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DUT | P33316 | 10/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013125 | 0.81 | CRBN (0.57) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL4278691 | 0.81 | PKM (0.38) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL24968966 | 0.79 | DUT (0.59) | CRBNALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL1923335 | 0.78 | PKM (0.61) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL4348697 | 0.77 | L3MBTL1 (0.59) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL6102943 | 0.75 | CRBN (0.56) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL5796880 | 0.75 | DUT (0.52) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL17254147 | 0.75 | ALDH1A1 (0.66) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL7231374 | 0.74 | PKM (0.53) | PKMCRBNALDH1A1LMNADUT | |
| SCHEMBL7588438 | 0.74 | PKM (0.49) | PKMCRBNALDH1A1LMNADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250171764-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2025-05-29 | — | — | US | disclosed |
| US-12234448-B2 | Purification of nucleic acids using titanium oxides | ABBOTT MOLECULAR INC. | 2025-02-25 | — | — | US | disclosed |
| WO-2024220575-A2 | REGULATING DISEASE OR DISORDER CHARACTERIZED BY ESOPHAGEAL EPITHELIAL PROLIFERATION THROUGH SECRETED FRIZZLED-RELATED PROTEIN 1 (SFRP1) | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024220570-A2 | C3D IMMUNOTHERAPIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024138008-A1 | DNA-BASED VECTOR DATA STRUCTURE WITH PARALLEL OPERATIONS | Catalog Technologies, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137794-A1 | DNA-BASED VECTOR DATA STRUCTURE WITH PARALLEL OPERATIONS | Catalog Technologies, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4352216-A1 | BASE EDITING OF TRANSTHYRETIN GENE | Beam Therapeutics Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4326334-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | GanNA Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024037578-A1 | COMPOSITION OF LIPID NANOPARTICLES | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-02-22 | — | — | WO | disclosed |
| WO-2002066641-A1 | PG-3 AND BIALLELIC MARKERS THEREOF | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
| WO-2001032885-A9 | HUMAN LIPASE | MILLENNIUM PHARM INC (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1159618-A1 | PROTEINS FOR DIAGNOSIS AND TREATMENT OF BREAST CANCER | Oxford GlycoSciences (UK) Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001053500-A1 | METHODS AND MATERIALS RELATING TO STEM CELL GROWTH FACTOR-LIKE POYPEPTIDES AND POLYNUCLEOTIDES | HYSEQ, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1116032-A1 | GPR10 AS A TARGET FOR IDENTIFYING WEIGHT MODULATING COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001042474-A2 | INTERFERON-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001032885-A2 | HUMAN LIPASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000055628-A1 | PROTEINS FOR DIAGNOSIS AND TREATMENT OF BREAST CANCER | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000018800-A9 | NOVEL SECRETED IMMUNOMODULATORY PROTEINS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000017641-A1 | GPR10 AS A TARGET FOR IDENTIFYING WEIGHT MODULATING COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | C5AR2, C3AR1, CFD | PKM 2694/4885CRBN 690/4885ALDH1A1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.